Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP), a biopharmaceutical development company, is focused on acquiring and developing innovative products designed to treat a variety of human diseases. Currently, the company is developing a portfolio of metabolically inert antifolate compounds engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. Chelsea Therapeutics purposes to create value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline. For further information, visit the Company’s web site at www.chelseatherapeutics.com.
- 17 years ago
QualityStocks
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharma company, has filed a patent application for NRX-100,…
-
ZDKL Champions World Peace Through Trade with Decentralized Tools for Global Commerce
Investor Brand Network ZDKL, a regulation-first blockchain project, has officially launched the Peace Through Trade…
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Ramps Up Innovation, Logistics to Power Growth
Massimo (NASDAQ: MAMO) is making strategic moves to actively enhance its position in the powersports and…